

Overview of CML related sessions at EHA 2022 Hybrid Congress

June 9-12, 2022 (Live streamed program)

June 15-17 (Virtual thematic days)

All sessions will be held at CEST (Central European Summer Time)

Time slots	Sessions
Live streamed sessions	
June 9 (Thursday) 14.45 – 16.15 CEST Room SS9034	<p>Satellite Symposium: (Supported by Novartis) The human impact of chronic myeloid leukemia (CML) after 2 TKIs: What does the data mean for patients and the clinical practice?</p> <p>Chair: A Hochhaus (Jena, Germany)</p> <p>Program:</p> <ul style="list-style-type: none"> • Welcome and introduction (A Hochhaus, Germany) • Remaining attentive: unmet needs and disease burden of CML (A Hochhaus, Germany) • Focusing on the data: efficacy and safety in later lines of current and emerging CML therapies (M Breccia, Italy) • Seeing the human impact: what does the data mean for the patient and for the clinical practice? (D Réa, France) • Forward facing: optimizing CML treatment in the future (D Milojkovic, UK) • Live panel discussion & Q&A (moderated by A Hochhaus) • Concluding remarks (A Hochhaus)
June 10 (Friday) 9.45 – 10.45 CEST	<p>Scientific Working Group Session – ELN-EHA-SWG for CML: Understanding the pathogenesis of CML</p>

Time slots	Sessions
	Chair: JF Apperley (London, UK) Program: <ul style="list-style-type: none"> • Lessons from EUTOS 2018-2021 (K Machova Polakova, Czech Republic) • Non-BCR-ABL1 molecular biomarkers of prognosis (S Awad, Finland) • Mechanisms of stem cell persistence in CML (M Schemionek-Reinders, Germany) • Mechanisms of disease progression in CML (S Tiong Ong, Singapore)
June 12 (Sunday) 8.00 – 9.30 CEST	Education Session: Novel perspectives in MPN and CML Chair: H. Gisslinger (Austria) Program: <ul style="list-style-type: none"> • Understanding the megakaryopoiesis in MPN (B Psaila, UK) • New targets: Can we achieve disease modification in MF? (JJ Kiladjan, France) • Safe pregnancy and healthy babies in CML. How-to-do-it? (E Abruzzese, Italy)
Advocacy & Patient Sessions	
June 10 (Friday) 8.00 – 9.30 CEST	EHA-Patient Joint Symposium <ul style="list-style-type: none"> • Session I: From drug-centric to patient-centric (part 1): clinical trials (Session details to be announced)
June 10 (Friday) 9.30 – 11.00 CEST	EHA-Patient Joint Symposium <ul style="list-style-type: none"> • Session II: Europe's Beating Cancer Plan (Session details to be announced)
June 15 (Wed.)	EHA Symposium on Patient Communication: Embracing challenging emotions

Time slots	Sessions
8.30 – 9.30 CEST	Session details to be announced
June 16 (Thursday) 10.45 – 11.45 CEST	EHA-Patient Joint Symposium Session details to be announced
June 17 (Friday) 10.45 – 11.45 CEST	EHA-Patient Joint Symposium Session details to be announced
Oral Presentations	
New insights into CML biology June 11 (Saturday) 11.30 – 12.45 CEST	<ul style="list-style-type: none"> • S150: BIOLOGY AND FUNCTION OF CIRCULAR PCMDT1 IN CHRONIC MYELOID LEUKEMIA IN BLAST CRISIS (CML-BC) (Prathap Urs A et al.) • S151: HIGH-THROUGHPUT EVALUATION OF THE POTENTIAL OF CANCER DRUGS TO ENHANCE NATURAL KILLER CELL IMMUNOTHERAPY IN CHRONIC MYELOID LEUKEMIA (Nygren P et al.) • S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS (Mancini M et al.) • S153: DECRYPTING THE ROLE OF HSP90A AND B ISOFORMS TO OVERCOME RESISTANCE IN BCR-ABL1 LEUKEMIA (Vogt M et al.) • S154: IMATINIB-RESISTANT CLONES ISOLATED FROM A MODEL OF BLAST CRISIS OF CHRONIC MYELOID LEUKAEMIA DIFFER IN MUTATIONS IN BCR::ABL1 AND OTHER CANCER RELATED GENES AND IN THEIR SENSITIVITY TO BH3-MIMETICS (Laznicka A et al.)
Treatment and monitoring in CML June 12 (Sunday)	<ul style="list-style-type: none"> • S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE (Réa D et al.)

Time slots	Sessions
11.30 – 12.45 CEST	<ul style="list-style-type: none"> • S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA (Pane F et al.) • S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT-LEVEL META-ANALYSIS (Kockerols C et al.) • S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB (Kim D et al.) • S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT (Busque L et al.)
e-Posters	
CML – Biology and Translational Research	<ul style="list-style-type: none"> • P690: GENE MUTATIONAL PROFILE ASSOCIATED WITH TREATMENT FAILURE OR PROGRESSION IN CHRONIC MYELOID LEUKEMIA (Estrada N et al)
CML - Clinical	<ul style="list-style-type: none"> • P695: PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML (Bidikian A et al) • P702: FIRST INTERIM RESULTS OF THE PROSPECTIVE STUDY OF DOSE REDUCTION AND DISCONTINUATION OF TYROSINE KINASE INHIBITORS (READIT-2020) IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE (Gurianova M et al.) • P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS (Haddad F et al) • P713: REAL-WORLD MANAGEMENT OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML): FIRST ANALYSIS FROM THE UK NATIONAL REGISTRY FOR CML (Nesr G et al.) • P718: ASCIMINIB MANAGED-ACCESS PROGRAM (MAP) IN RUSSIA (Shukhov O et al.)

Time slots	Sessions
Poster presentations	
<p>CML – Biology and Translational Research</p> <p>June 10 (Friday) 16.30 – 17.45 CEST</p>	<ul style="list-style-type: none"> • P688: VIRTUAL SCREENING PROTOCOL TO IDENTIFY TYROSINE KINASE INHIBITORS WITH A POTENTIAL TO INTERACT WITH P-GLYCOPROTEIN AND TO ACT AS MDR CHEMOSENSITIZERS: A VALIDATION STUDY (Beleva B et al.) • P691: MODELLING OF IMMUNE RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS SUGGESTS POTENTIAL FOR TREATMENT REDUCTION PRIOR TO CESSATION (Glauche I et al.) • P692: IMMUNE FACTORS MAINTAINING TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF IMATINIB (Kwasnik P et al.) • P693: DIAGNOSTIC ROLE OF CD26+ LEUKEMIC STEM CELLS IN CHRONIC MYELOID LEUKEMIA (Tiwari S et al.) • P694: INVESTIGATING THE ROLE OF CELL ADHESION MOLECULES IN TUNNELING NANOTUBES FORMATION IN CHRONIC MYELOID LEUKEMIA MICROENVIRONMENT (Turos-Korgul L et al.)
<p>CML – Clinical</p> <p>June 10 (Friday) 16.30 – 17.45 CEST</p>	<ul style="list-style-type: none"> • P696: SUBTHERAPEUTIC TKI DOSES FOR THE MAINTENANCE OF CML PATIENTS WITH INTOLERANCE OR REFUSAL TO DISCONTINUE: A SINGLE CENTER FEASIBILITY STUDY (Borrero A et al.) • P697: PONATINIB IN A REAL-LIFE SETTING: A RETROSPECTIVE ANALYSIS FROM THE MONITORING REGISTRIES OF THE ITALIAN MEDICINES AGENCY (AIFA) (Breccia M et al.) • P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY (Castagnetti F et al.) • P699: REAL-LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5-YEAR-DATA FROM A BELGIAN REGISTRY

Time slots	Sessions
	<p>(Devos T et al.)</p> <ul style="list-style-type: none"> • P700: TREATMENT-FREE REMISSION (TFR) AFTER DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND DEEP MOLECULAR RESPONSE (DMR): FINAL 5-YEAR RESULTS OF DASFREE (Shah NP et al.) • P701: COVID-19 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN TREATMENT-FREE REMISSION: DISEASE SEVERITY AND IMPACT ON TFR STATUS (Hughes T et al.) • P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL (Hughes T et al.) • P705: MULTI-CENTER CHART REVIEW STUDY EXAMINING TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS WITH CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) TREATED IN THIRD-LINE (3L) OR LATER IN FRANCE (Huynh L et al.) • P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE (Innes A et al.) • P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS (Apperley J et al.) • P708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY. (Khadadah F et al.) • P709: CLINICAL OUTCOME OF ASCIMINIB TREATMENT IN A REAL-WORLD MULTI-RESISTANT CML PATIENT POPULATION (Kockerols CB et al.) • P710: CLINICAL STUDY ON THE RELATIONSHIP BETWEEN NON-ABL1 KINASE REGION MUTATION AND TKI DRUG RESISTANCE AND DISEASE PROGRESSION IN CHRONIC MYELOID LEUKEMIA (Xiadong L et al.) • P711: KINETICS OF CITED2 GENE EXPRESSION IN CHRONIC MYELOID LEUKEMIA PATIENTS (Atef B et al.) • P712: ASCIMINIB ITALIAN MANAGED ACCESS PROGRAM: EFFICACY PROFILE IN HEAVILY

Time slots	Sessions
	<p>PRE-TREATED CML PATIENTS (Breccia M et al)</p> <ul style="list-style-type: none"> • P714: EFFECT OF TYROSINE KINASE INHIBITORS ON MALE FERTILITY IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA (Nesr G et al.) • P715: MULTICENTER OBSERVATIONAL STUDY OF PONATINIB IN CML PATIENTS IN ARGENTINA. REAL-WORLD EXPERIENCE (Pavlovsky C et al.) • P716: OUTCOMES AND PATTERNS OF TREATMENT IN CHRONIC MYELOID LEUKEMIA, A GLOBAL PERSPECTIVE BASED ON A REAL-WORLD DATA GLOBAL NETWORK (Sanz A et al.) • P717: BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL (Cortes JE et al) • P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER-LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB-ANALYSIS FROM THE PHASE 4 BYOND TRIAL (Gambacorti-Passerini C et al) • P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACY (Yeung D et al.) • P721: PREDICTIVE SCORING SYSTEMS FOR MOLECULAR RESPONSES IN PERSONS WITH CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL IMATINIB THERAPY (Zhang X et al.) • P722: IS THE SECOND-GENERATION TYROSINE KINASE INHIBITOR A BETTER THERAPY THAN IMATINIB FOR PERSONS WITH CHRONIC MYELOID LEUKEMIA PRESENTING IN ACCELERATED-PHASE? (Zhang X et al.)
For publication only	
CML – Biology and Translational Research	<ul style="list-style-type: none"> • PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML (Aloulou S et al.) • PB1892: IMATINIB RESISTANCE: THE ROLE OF PHARMACOGENETIC VARIABILITY IN A SOUTH AFRICAN COHORT (de Long C et al.) • PB1893: THE STUDY OF SET GENE AND PROTEIN PHOSPHATASE 2A IN CHRONIC MYELOID LEUKEMIA AND THEIR ROLE IN DISEASE PROGRESSION (Muhammed H et al.)

Time slots	Sessions
	<ul style="list-style-type: none"> • PB1894: MIR-199A EXPRESSION PROFILES IN CHRONIC MYELOID LEUKEMIA: A PRELIMINARY STUDY (Frikha R et al.) • PB1895: ANALYSIS REVEALS CANCER-ASSOCIATED GENE MUTATIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS : A CHINESE MONOCENTRIC RETROSPECTIVE STUDY (Huang J et al.) • PB1896: WHOLE EXOME SEQUENCING IDENTIFIES A NOVEL TRANSCRIPTION FACTOR ASSOCIATED WITH FATAL DISEASE PROGRESSION IN CHRONIC MYELOID LEUKEMIA (Iqbal Z et al.)
CML - Clinical	<ul style="list-style-type: none"> • PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE (Bouchakor Moussa Y et al.) • PB1898: BONE MARROW APLASIA – A RARE COMPLICATION OF IMATINIB THERAPY IN CML PATIENTS: ABOUT A CASE (Chawad W et al.) • PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST-LINE IMATINIB (Eskazan AE et al.) • PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS (Galdean SM et al.) • PB1901: KARYOTYPIC PROFILE OF CHRONIC MYELOID LEUKAEMIA DIAGNOSED AT TERTIARY LEVEL IN AFGHANISTAN (Maseh Haidary A et al.) • PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS (Breccia M et al.) • PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) (Hijiya N et al.) • PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) (Hughes T et al.)

Time slots	Sessions
	<ul style="list-style-type: none"> • PB1905: FEASIBILITY OF TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE: RESULTS FROM A SERIES OF 19 PATIENTS (Kacha F et al.) • PB1906: IS THERE A PLACE FOR IMATINIB IN THE FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA CHRONIC PHASE : REAL LIFE DATA FROM UNIVERSITY CENTER AFTER LONG PERIOD OF FOLLOW-UP (Lekovic D et al.) • PB1907: CLINICAL VALUE OF DETECTING ABL KINASE MUTATIONS IN CHRONIC MYELOID LEUKEMIA BASED ON HIGH THROUGHPUT SEQUENCING TECHNOLOGY (Lyu X et al.) • PB1908: COVID-19 INSIGHTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DIAGNOSIS AND TREATMENT (Musteata V et al.) • PB1909: A STUDY ON TROUGH LEVELS OF GENERIC DASATINIB AND ITS CORRELATION WITH ADVERSE EVENTS AND EFFICACY (Nair A et al.) • PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS (Joao Ramos M et al.) • PB1911: A COMPREHENSIVE EHEALTH IMPLEMENTTION GUIDE CONSTRUCTED ON A QUALITATIVE CASE STUDY ON BARRIERS AND FACILITATORS OF THE DIGITAL CARE PLATFORM CMYLIFE, FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Verweij L et al.)